CL2024001598A1 - Inhibidores de péptido del receptor de interleucina-23 - Google Patents

Inhibidores de péptido del receptor de interleucina-23

Info

Publication number
CL2024001598A1
CL2024001598A1 CL2024001598A CL2024001598A CL2024001598A1 CL 2024001598 A1 CL2024001598 A1 CL 2024001598A1 CL 2024001598 A CL2024001598 A CL 2024001598A CL 2024001598 A CL2024001598 A CL 2024001598A CL 2024001598 A1 CL2024001598 A1 CL 2024001598A1
Authority
CL
Chile
Prior art keywords
interleukin
peptide inhibitors
receptor peptide
compounds
diseases
Prior art date
Application number
CL2024001598A
Other languages
English (en)
Spanish (es)
Inventor
Fischer Munch Henrik
Bjerre HOLM Niels
Leth Rasmus
Due Larsen Bjarne
Mosolff Mathiesen Jesper
Caldararu Octav
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of CL2024001598A1 publication Critical patent/CL2024001598A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024001598A 2021-12-01 2024-05-28 Inhibidores de péptido del receptor de interleucina-23 CL2024001598A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP21211815 2021-12-01

Publications (1)

Publication Number Publication Date
CL2024001598A1 true CL2024001598A1 (es) 2024-11-15

Family

ID=78821013

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024001598A CL2024001598A1 (es) 2021-12-01 2024-05-28 Inhibidores de péptido del receptor de interleucina-23

Country Status (12)

Country Link
US (1) US20250154198A1 (cg-RX-API-DMAC7.html)
EP (1) EP4440592A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024543204A (cg-RX-API-DMAC7.html)
KR (1) KR20240111800A (cg-RX-API-DMAC7.html)
CN (1) CN118354781A (cg-RX-API-DMAC7.html)
AU (1) AU2022402440A1 (cg-RX-API-DMAC7.html)
CA (1) CA3240982A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001598A1 (cg-RX-API-DMAC7.html)
IL (1) IL313185A (cg-RX-API-DMAC7.html)
MX (1) MX2024006556A (cg-RX-API-DMAC7.html)
TW (1) TW202332682A (cg-RX-API-DMAC7.html)
WO (1) WO2023099669A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4471048A1 (en) * 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) * 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121794283A (zh) * 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026815A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
HK1257747A1 (zh) 2015-07-15 2019-10-25 Protagonist Therapeutics Inc. 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途
WO2018022937A1 (en) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
JP2020505352A (ja) 2017-01-18 2020-02-20 プロタゴニスト セラピューティクス, インコーポレイテッド インターロイキン−23受容体のペプチド阻害剤および炎症性疾患を治療するためのそれらの使用
CA3104418A1 (en) 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2020311395A1 (en) 2019-07-10 2022-02-03 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2022008740A (es) * 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
WO2021146458A1 (en) 2020-01-15 2021-07-22 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie

Also Published As

Publication number Publication date
AU2022402440A1 (en) 2024-05-30
CA3240982A1 (en) 2023-06-08
IL313185A (en) 2024-07-01
JP2024543204A (ja) 2024-11-19
EP4440592A1 (en) 2024-10-09
CN118354781A (zh) 2024-07-16
KR20240111800A (ko) 2024-07-17
MX2024006556A (es) 2024-06-12
TW202332682A (zh) 2023-08-16
WO2023099669A1 (en) 2023-06-08
US20250154198A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
MX2024006556A (es) Inhibidores de peptido del receptor de interleucina-23.
MA58170B1 (fr) Dérivés carboxy avec des proprietes anti-inflammatoires
MX2018011392A (es) Composiciones canabinoides y basadas en canabis y metodos para el tratamiento de condiciones inflamatorias del tracto gastrointestinal.
BR112022014011A2 (pt) Inibidores peptídicos de receptor de interleucina-23 e seu uso no tratamento de doenças inflamatórias
UY27627A1 (es) Aza - arilpiperazinas
EA201890618A1 (ru) Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
CL2017002825A1 (es) Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2
EP3999121A4 (en) TREATMENT/PREVENTION OF DISEASE BY INHIBITION OF LING COMPLEX
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EP3601531C0 (en) TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH LIVE BIOTHERAPEUTICS
MA50013B1 (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton
AR070561A1 (es) Anillos intravaginales monoliticos que comprenden progesterona y metodos para su fabricacion y uso
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
JOP20230186A1 (ar) أجسام مضادة لـ cd30l واستخداماتها
CR10387A (es) Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepin-4-il] amina como moduladores del potencial transitorio de receptor vaillinoide 1 para el tratamiento de dolor
EA201991387A1 (ru) ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ
MX2024006975A (es) Inhibidor de cdk9 y uso del mismo.
MX2025013162A (es) Preparacion de peptido inhibidor del receptor de interleucina-23 y uso del mismo
CO2024016062A2 (es) Nuevos péptidos como antagonistas selectivos del receptor de la il-23
MX2022008265A (es) Compuestos y metodos para el tratamiento del dolor visceral.
Petrelli et al. Poly (ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice
Zhou et al. Design and synthesis of nanofibers of self-assembled de novo glycoconjugates towards mucosal lining restoration and anti-inflammatory drug delivery
EP3440045A4 (en) PREVENTING, TREATING AND REVERSING DISEASES USING THERAPEUTICALLY ACTIVE AMOUNTS OF DICARBONIC ACID COMPOUNDS
EP2231148A4 (en) Pharmaceutical composition for the treatment and prevention of heart disease
PH12018502703A1 (en) An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients